Syntara Ltd
ASX:SNT
Syntara Ltd
Operating Expenses
Syntara Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Syntara Ltd
ASX:SNT
|
Operating Expenses
-AU$19.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Operating Expenses
-AU$381.1m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Operating Expenses
-AU$38.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-13%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Operating Expenses
-AU$12.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-37%
|
|
|
Probiotec Ltd
ASX:PBP
|
Operating Expenses
-AU$46.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-7%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Operating Expenses
-AU$33.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
Syntara Ltd
Glance View
Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
See Also
What is Syntara Ltd's Operating Expenses?
Operating Expenses
-19.5m
AUD
Based on the financial report for Jun 30, 2024, Syntara Ltd's Operating Expenses amounts to -19.5m AUD.
What is Syntara Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
8%
Over the last year, the Operating Expenses growth was -8%. The average annual Operating Expenses growth rates for Syntara Ltd have been 9% over the past three years , 8% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet